Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1Erectile Dysfunction 1

Interventions

Sildenafil Citrate 8Tadalafil 4Surveys and Questionnaires 2Alprostadil 2mirabegron 1methyl 3-mercaptopropionimidate 1bicalutamide 1Yoga 1Tamoxifen 1Tacrolimus 1Tablets 1Surgical Instruments 1Saline Solution 1Restraint, Physical 1Psychiatric Rehabilitation 1Preservation, Biological 1Pentoxifylline 1Menogaril 1Intraoperative Neurophysiological Monitoring 1High-Intensity Focused Ultrasound Ablation 1GPI 1485 1Erythropoietin 1Educational Status 1Early Intervention, Educational 1Dutasteride 1Cyproterone Acetate 1Cell- and Tissue-Based Therapy 1Arginine 1ArginMax 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Erectile Dysfunction × 4-Aminopyridine × Genitourinary × Clear all
NCT03701581 2025-12-17

4-aminopyridine Treatment for Nerve Injury

University of Arizona

Phase 2/3 Recruiting
70 enrolled
Genitourinary

Erectile Dysfunction, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡